Clinical Lymphoma Myeloma and Leukemia 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.SOHO State of the Art Updates and Next Questions: Will CAR-T Replace ASCT in NDMM
The treatment landscape for multiple myeloma (MM) has rapidly evolved over the last 2 decades. The development of triplet and quadruplet regimens including proteasome inhibitors (PI), immunomodulatory agents (IMiDs), and anti-CD38 monoclonal antibodies has dramatically extended overall survival. In addition to effective multidrug regimens, autologous stem cell transplant (ASCT) is a cornerstone of management in newly diagnosed multiple myeloma (NDMM). However, despite these combined treatment modalities, curative therapy for MM remains elusive. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 18, 2024 Category: Hematology Authors: Eric Jurgens, Saad Z. Usmani Tags: Review Article Source Type: research
SOHO State of the Art Updates and Next Questions | Will CAR-T Replace ASCT in NDMM?
The treatment landscape for multiple myeloma (MM) has rapidly evolved over the last two decades. The development of triplet and quadruplet regimens including proteasome inhibitors (PI), immunomodulatory agents (IMiDs), and anti-CD38 monoclonal antibodies has dramatically extended overall survival. In addition to effective multidrug regimens, autologous stem cell transplant (ASCT) is a cornerstone of management in newly diagnosed multiple myeloma (NDMM). However, despite these combined treatment modalities, curative therapy for MM remains elusive. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 18, 2024 Category: Hematology Authors: Eric Jurgens, Saad Z. Usmani Tags: Review Article Source Type: research
Serologic Response to Vaccine for COVID-19 in Patients with Hematologic Malignancy: A Prospective Cohort Study
Patients with hematologic malignancies have increased mortality due to COVID-19.1 A recent systematic review reported a fatality rate of up to 40% for patients with hematologic cancer and SARS-CoV-2 infection, significantly higher than the 3.6% fatality rate reported in the literature for the general population.2 Vaccination responses are known to be attenuated in patients with hematologic malignancies. Monin et al. reported that 18% of patients with hematologic cancers had positive anti-S IgG titers three weeks after receiving a single dose of the BNT162b2 vaccine compared to 94% of healthy controls and 38% of patients wi...
Source: Clinical Lymphoma, Myeloma and Leukemia - January 18, 2024 Category: Hematology Authors: Alexandra Hillyer, Anthony Quint, Artin Ghassemian, Nicolette Joh-Carnella, Michael J. Knauer, Danny Dawd, Alejandro Lazo-Langner, Joy Mangel, Selay Lam, Husam Abdoh, Anargyros Xenocostas, Uday Deotare, Lalit Saini, Cheryl Foster, Martha Louzada, Jenny Ho Source Type: research
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial
Acute myeloid leukemia (AML) is an aggressive malignancy, and largely a disease of older patients, with a median age at diagnosis of 68 years.1 Therapies for patients with relapsed or refractory (R/R) AML remain limited and outcomes poor, especially for patients who are ineligible for cytotoxic chemotherapy or targeted therapies.2-6 Therapies that target survival pathways known to be dysregulated or aberrant in AML may improve outcomes, particularly if they are less toxic. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 18, 2024 Category: Hematology Authors: Marina Y. Konopleva, Monique Dail, Naval G. Daver, Jacqueline S. Garcia, Brian A. Jonas, Karen W.L. Yee, Kevin R. Kelly, Norbert Vey, Sarit Assouline, Gail J. Roboz, Stefania Paolini, Daniel A. Pollyea, Agostino Tafuri, Joseph M. Brandwein, Arnaud Pigneux Tags: Original Study Source Type: research
Geographic and Racial Disparities in Chimeric Antigen Receptor –T Cells and Bispecific Antibodies Trials Access for Diffuse Large B-Cell Lymphoma
We investigate the geographical and racial disparities in accessing CAR-T and bispecific antibodies trials for DLBCL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 17, 2024 Category: Hematology Authors: Moazzam Shahzad, Muhammad Fareed Khalid, Muhammad Kashif Amin, Ahmad Basharat, Mohammad Ammad-Ud-Din, Robin Park, Iqra Anwar, Muhammad Salman Faisal, Michael Jaglal Tags: Original Study Source Type: research
Geographic and Racial Disparities in Chimeric Antigen Receptor –T Cells and Bi-specific Antibodies Trials Access for Diffuse Large B-Cell Lymphoma
We investigate the geographical and racial disparities in accessing CAR-T and bispecific antibodies trials for DLBCL. ClinicalTrials.gov was searched, and 75 trials with at least one open site in the US were included. 2020 US Census Bureau data was used to obtain data on race and ethnicity. SPSS version 26 was used for analysis. There were 62 CAR-T and 13 bispecific antibodies trials with 6221 enrolled or expected to enroll patients. 85% of the clinical trials were only open in the US, and the majority 64% were pharmaceutical-funded. There were 126 unique study sites distributed over 31 states with 11 (0-51) mean number ...
Source: Clinical Lymphoma, Myeloma and Leukemia - January 17, 2024 Category: Hematology Authors: Moazzam Shahzad, Muhammad Fareed Khalid, Muhammad Kashif Amin, Ahmad Basharat, Mohammad Ammad-Ud-Din, Robin Park, Iqra Anwar, Muhammad Salman Faisal, Michael Jaglal Source Type: research
Prognostic Impact of Bone Marrow Fibrosis And Effects of Tyrosine Kinase Inhibitors on Bone Marrow Fibrosis in Chronic Myeloid Leukemia
Myelofibrosis is reported in around 40% of newly diagnosed chronic myeloid leukemia (CML) patients and have an important role in the pathobiology and prognosis of CML. This retrospective study aimed to evaluate the effects of bone marrow (BM) fibrosis on disease prognosis and the effects of specific tyrosine-kinase inhibitors (TKIs) on BM fibrosis in CML patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 16, 2024 Category: Hematology Authors: Mehmet Sezgin Pepeler, Mesut T ıglıoglu, Simten Dagdas, Esra Ozhamacıoglu, Unsal Han, Aynur Albayrak, Mürüvvet Seda Aydın, Gülten Korkmaz, Merve Pamukcuoğlu, Funda Ceran, Murat Albayrak, Gülsüm Ozet Tags: Original Study Source Type: research
A review of the therapeutic role of bosutinib in chronic myeloid leukemia
The development of the BCR::ABL1 tyrosine kinase inhibitors (TKIs) has transformed Philadelphia chromosome (Ph) –positive chronic myeloid leukemia (CML) from a fatal disease to an often-indolent illness that, when managed effectively, can restore a life expectancy close to that of the normal population. Bosutinib is a second-generation TKI approved for adults with Ph-positive CML in chronic phase, accelerat ed phase, or blast phase that is resistant or intolerant to prior therapy, and for newly diagnosed Ph-positive chronic phase CML. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 11, 2024 Category: Hematology Authors: H.M. Kantarjian, E.J. Jabbour, J.H. Lipton, F. Castagnetti, T.H. Br ümmendorf Tags: Review Article Source Type: research
Chimeric Antigen Receptor T - Cell Therapy for Large B-Cell Lymphoma Patients with Central Nervous System Involvement, a Systematic Review and Meta-analysis
Chimeric Antigen Receptor T-cell (CAR T-cell) therapy is an effective treatment for relapsed/refractory (R/R) large B cell lymphoma (LBCL). However, patients with central nervous system (CNS) lymphoma were excluded in most of the CAR T-cell therapy trials. This meta-analysis assesses the efficacy with CAR T-cell therapy in LBCL patients with CNS involvement. Two reviewers independently searched PubMed and Cochrane Library to identify all published literature associated with United States Food and Drug Administration (U.S. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 11, 2024 Category: Hematology Authors: Ghada Elgohary, Yang Yang, Mia Gergis, Dongni Yi, Usama Gergis Tags: Review Article Source Type: research
SOHO State of the Art Updates and Next Questions | CTLs for Infections Following Stem Cell Transplantation
Allogeneic hematopoietic stem cell transplantation (AHSCT) is an important modality in the treatment of acute leukemia and other hematologic disorders. The post-transplant period is associated with prolonged periods of impaired immune function. Delayed T-cell immune reconstitution is correlated with increased risk of viral, bacterial, and fungal infections. This risk increases with high intensity inductions regimens often required for alternative donor sources. Current therapies for prophylaxis and treatment of these infections are limited by poor efficacy and significant toxicity. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 8, 2024 Category: Hematology Authors: Ariel Rischall, Amanda Olson Tags: Review Article Source Type: research
SOHO State of the Art Updates and Next Questions | Next Questions: Acute Lymphoblastic Leukemia
The integration of immune and targeted therapies into the treatment of acute lymphoblastic leukemia (ALL) has significantly improved outcomes, reduced the intensity and duration of chemotherapy, and the reliance on allogeneic stem cell transplantation (SCT). In younger patients with Philadelphia chromosome (Ph)-negative ALL, treatment with Hyper-CVAD and blinatumomab +/- inotuzumab has improved the 3-year overall survival (OS) to above 85%. In older patients, using less intensive chemotherapy (mini-Hyper-CVD) in combination with inotuzumab and blinatumomab has improved the 5-year OS rate to 50%. (Source: Clinical Lymphoma,...
Source: Clinical Lymphoma, Myeloma and Leukemia - January 8, 2024 Category: Hematology Authors: Jayastu Senapati, Hagop Kantarjian, Fadi G. Haddad, Nicholas J. Short, Mary Alma Welch, Nitin Jain, Elias Jabbour Tags: Review Article Source Type: research
SOHO State of the Art Updates and Next Questions ࣦ CTLs for Infections Following Stem Cell Transplantation
Allogeneic hematopoietic stem cell transplantation (AHSCT) is an important modality in the treatment of acute leukemia and other hematologic disorders. The post-transplant period is associated with prolonged periods of impaired immune function. Delayed T-cell immune reconstitution is correlated with increased risk of viral, bacterial, and fungal infections. This risk increases with high intensity inductions regimens often required for alternative donor sources. Current therapies for prophylaxis and treatment of these infections are limited by poor efficacy and significant toxicity. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 8, 2024 Category: Hematology Authors: Ariel Rischall, Amanda Olson Tags: Review Article Source Type: research
An Open-Label Phase I Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma
A therapeutic combination of metformin, nelfinavir, and bortezomib is feasible for multiple myeloma patients with relapsed and/or refractory disease. While no dose-limiting toxicities were observed, no objective responses were observed either in the dose levels evaluated in this study. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 6, 2024 Category: Hematology Authors: Ibrahim Alodhaibi, Sikander Ailawadhi, Gabriel P. Burbano, Patrick J. O'Brien, Francis K. Buadi, Suzanne Hayman, Shaji K. Kumar, Wilson I. Gonsalves Tags: Original Study Source Type: research
An Open-Label Phase 1 Study of Metformin and Nelfinavir in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma
In preclinical models, combining a GLUT4 inhibitor with an oxidative phosphorylation inhibitor shows synergistic therapeutic potential against multiple myeloma (MM). Thus, this study evaluated the safety and tolerability of repurposing metformin, a complex I inhibitor, and nelfinavir, a GLUT4 inhibitor, in combination with bortezomib for the treatment of relapsed/refractory MM that had progressed on all standard of care (SOC) therapies. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 6, 2024 Category: Hematology Authors: Ibrahim Alodhaibi, Sikander Ailawadhi, Gabriel Perez Burbano, Patrick J. O'Brien, Francis K. Buadi, Suzanne Hayman, Shaji K. Kumar, Wilson I. Gonsalves Tags: Original Study Source Type: research
Corrigendum to “AML-068 - Survival Differences in Patients With Acute Myeloid Leukemia (AML) Treated With Oral Azacitidine (Oral-AZA) as Maintenance and Those Eligible but Not Treated in a US Electronic Health Record (EHR) Database” [Clinical Lymphoma, Myeloma & Leukemia, 23S1 (2023) S1-S593]
Alice Mims, MD1, Zhuoer Xie, MD2, Alberto Vasconcelos, MD3, Maria Strocchia, PharmD, PhD3, Willem Heydendael, PhD3, Manoj Chevli MPharm, MSc3, David Rotter, PhD4, Ravi Potluri, MBA4, Thomas Prebet, MD, PhD3, Jan Sieluk, PharmD, PhD3,*jan.sieluk@bms.com (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 4, 2024 Category: Hematology Authors: Alice Mims, Zhuoer Xie, Alberto Vasconcelos, Maria Strocchia, Willem Heydendael, Manoj Chevli, David Rotter, Ravi Potluri, Thomas Prebet, Jan Sieluk Tags: Corrigendum Source Type: research
